Podcast
AUAUniversity
Hosted by American Urological Association · EN
The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
46episodes
Episodes
Newest firstAll episodes
AUA2026: Focus on: ADT in the Modern Era
2d ago01:09:10Tap to summarizeAUA2026: Focus on: ADT in the Modern Era - Balancing Cancer Control and Cardiovascular Safety CME Available: https://cme.auanet.org/URL/FOCUS265ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Integrate cardiovascular (CV) risk assessment into ADT initiation by applying key findings from the REVELUTION-1 trial to identify patients at elevated risk for atherosclerosis and MACE. 2. Compare and apply the CV safety profiles of LHRH agonists versus GnRH receptor antagonists to guide personalized ADT selection in patients with varying CV risk. 3. Implement streamlined monitoring strategies for men on oral ADT, including testosterone levels, lipid and blood pressure evaluation, and surveillance for early CV risk indicators. 4. Collaborate with cardiology and primary care to optimize statin use and coordinate CV risk-reduction strategies for prostate cancer patients receiving ADT. 5. Strengthen shared decision making and adherence by incorporating discussions of oncologic benefit, CV risk, and mitigation strategies into routine oral ADT counseling and follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Pfizer, Inc Sumitomo Pharma America, Inc.
Transcribe →Innovations in the Surgical Management of BPH (2026)
1w ago00:36:22Tap to summarizeInnovations in the Surgical Management of BPH (2026) CME Available: https://cme.auanet.org/URL/surgical-treatment-bph-2026 LEARNING OBJECTIVES: After participating in this educational series, participants will be able to: 1. Utilize the newly released AUA Guidelines Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice. 2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them. 3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics. 4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: - Olympus Corporation of the Americas - Teleflex Interventional Urology © 2026 AMERICAN UROLOGICAL ASSOCIATION. ALL RIGHTS RESERVED. ATTENTION: You are prohibited from using or uploading content you accessed through this activity into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Transcribe →Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach
2w ago00:35:09Tap to summarizeUpdate Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026
Transcribe →AUA Guidelines: Advanced Prostate Cancer
3w ago00:22:42Tap to summarizeAUA Guidelines: Advanced Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Kristen R. Scarpato, MD, MPH To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer
Transcribe →AUA2026: Focus on: Metastatic Urothelial Carcinoma (mUC)
Jun 1701:07:37Tap to summarizeAUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.
Transcribe →AUA Guidelines: Clinically Localized Prostate Cancer
Jun 1000:28:18Tap to summarizeAUA Guidelines: Clinically Localized Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: James Eastham, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer
Transcribe →Update Series (2026): Kidney Stones and the Infected Patient
Jun 300:21:28Tap to summarizeUpdate Series (2026): Kidney Stones and the Infected Patient Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Mantu Gupta, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org
Transcribe →AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast
May 2701:15:42Tap to summarizeAUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging
Transcribe →AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team
May 2000:46:22Tap to summarizeAUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://cme.auanet.org/URL/PARP26ONL LEARNING OBJECTIVES: At the conclusion of this CME activity, participants will be able to: 1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination. 2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC. 3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC. 4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life. 5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment. 5. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astrazeneca Merck & Co., Inc Pfizer, Inc.
Transcribe →Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines
May 1300:41:35Tap to summarizeUpdate Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026
Transcribe →